Clinical trials: COVID-19
COVID-19 Pneumonia
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05057923
- Testing
- Bacillus subtilis
- Where
- Hong Kong
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
Healthy, COVID-19
Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects
This is a randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, and pharmacokinetics of ASC11 plus ritonavir tablets in healthy subjects and an open-label, cross-over study…
- Trial name
- NCT05718518
- Testing
- ASC11 tablets, RTV tablets
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
COVID-19, SARS-CoV-2 Infection
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment.
- Trial name
- SARS-CoV-2 (NCT04465981)
- Testing
- Sampling
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- INanoBio Inc.
Confirmed Coronavirus Disease
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e.
- Trial name
- NCT04530136
- Testing
- Ruconest
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pharming Technologies B.V.
COVID-19
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
The primary objective of the study was to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection…
- Trial name
- NCT04380519
- Testing
- RPH-104 80 mg, Olokizumab 64 mg
- Where
- 16 sites in Russia
- Volunteers
- 372 people
- Sponsor
- R-Pharm International, LLC
Long COVID
Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)
This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed…
- Trial name
- NCT06637800
- Testing
- Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
- Where
- Mexico
- Sponsor
- ExThera Medical Corporation
COVID-19
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
- Trial name
- SPRINT (NCT05616728)
- Testing
- EDP-235
- Where
- 23 sites in United States, Romania
- Volunteers
- 231 people
- Sponsor
- Enanta Pharmaceuticals, Inc
COVID-19
COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19
The primary objectives of the study are: To characterize the concentrations of casirivimab+imdevimab in serum over time To evaluate the safety and tolerability of casirivimab+imdevimab The secondary objective of the study is: To…
- Trial name
- NCT05092581
- Testing
- casirivimab+imdevimab
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Regeneron Pharmaceuticals
Covid19
Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test on samples collected by a healthcare professional versus self-collection; and to perform analysis to compare results.
- Trial name
- NCT04805892
- Testing
- BIOZEK COVID-19 Antigen Rapid Test
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mach-E B.V.
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077332
- Testing
- Famotidine, Celecoxib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
COVID19, Sars-Cov-2
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein.
- Trial name
- COV2NOSE (NCT06851611)
- Testing
- COVID-19 vaccine, low dose level, COVID-19 vaccine, high dose level, Nasal Drops
- Where
- Finland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
Post COVID-19 Syndrome
Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome
This study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10 weeks with two follow-up visits and an end of…
- Trial name
- HBPCOVID02 (NCT05126563)
- Testing
- HB-adMSCs (allogeneic)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Hope Biosciences Research Foundation
COVID-19 Drug Treatment
Telmisartan for Treatment of COVID-19 Patients
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic.
- Trial name
- NCT04355936
- Testing
- Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
- Where
- 2 sites in Argentina
- Volunteers
- 400 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
COVID-19, SARS-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
The objective of study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E as booster compared with Sinopharm inactivated COVID-19 vaccine as booster.
- Trial name
- NCT05239806
- Testing
- SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.
- Trial name
- NCT04632706
- Testing
- Ivermectin
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MedinCell S.A
Relapsing Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation…
- Trial name
- KYRIOS (NCT04869358)
- Testing
- Ofatumumab
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older.
- Trial name
- NCT04869592
- Testing
- low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell), high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- Where
- China
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Bioavailability
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants.
- Trial name
- NCT05263921
- Testing
- PF-07321332/ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19
Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents
This Phase 1 trial is an open-label trial to evaluate the safety, reactogenicity and immunogenicity of two dosages (10^6 PFU and 10^7 PFU) of intranasal CVXGA1 administered as a single dose in healthy adults age 18-55 years and…
- Trial name
- CVXGA1-001 (NCT04954287)
- Testing
- CVXGA1 low dose, CVXGA1 high dose
- Where
- 4 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
SARS-CoV-2, Covid-19
Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test
The SARS-CoV-2 Antigen Rapid Test is a bioassay intended for rapid point-of-care detection of the SARS-CoV-2 virus. Performance of the SARS-CoV-2 Antigen Rapid Test assay will be assessed by comparison to a reference method.
- Conditions
- SARS-CoV-2, Covid-19, Coronavirus
- Trial name
- NCT04808921
- Testing
- Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test
- Where
- United States
- Sponsor
- Sky Medical Supplies & Equipments, LLC